Although ICIs such as PD-1 blockers (e.g., pembrolizumab) and anti-VEGFA agents (e.g., bevacizumab) have revolutionized cancer treatment, their efficacy is often compromised by resistance mechanisms, including compensatory angiogenic pathways and immune evasion (2, 40). The gene discussed is PDCD1; the disease is cancer.